The National Pharmaceutical Pricing Authority (NPPA), under the Ministry of Chemicals and Fertilizers, has announced an increase in the prices of over 900 essential medicines, effective from April 1, 2025. This price hike, up to 1.74%, includes a range of crucial medications used to treat critical infections, heart diseases, and diabetes. The revision of these prices is a part of the annual adjustment based on the Wholesale Price Index (WPI), as mandated by the Drugs (Prices Control) Order, 2013 (DPCO, 2013).
According to Minister of State for Chemicals and Fertilizers, Anupriya Patel, these price adjustments reflect the annual change in the WPI, which saw an increase of 1.74% during the 2024 calendar year compared to 2023. The price of essential medicines is revised each year to ensure that it aligns with inflationary trends and other market conditions. The new ceiling prices will apply to scheduled medicines, which are regularly monitored and regulated by the NPPA.
Among the medicines affected by the price revision, the widely used antibiotic azithromycin will see a price increase. The price of the 250mg and 500mg tablet of azithromycin will rise to ₹11.87 and ₹23.98 per tablet, respectively. Additionally, dry syrups containing amoxicillin and clavulanic acid will now cost ₹2.09 per milliliter. These price hikes are expected to affect the affordability of critical medicines, particularly for low-income patients who rely heavily on these treatments.
The NPPA’s role in regulating medicine prices is crucial in ensuring that life-saving drugs remain accessible, although price hikes can place additional financial burdens on consumers. The price changes will be applicable across the country, and consumers are advised to be aware of the new rates when purchasing medications. These changes also reflect the growing pressure on the pharmaceutical sector due to fluctuating raw material costs and the ongoing global economic situation.
As these price increases take effect, the NPPA’s continuous efforts to regulate and monitor the cost of essential medicines remain important for maintaining the balance between affordability and sustainability in the healthcare sector.
